Esther Duruchukwu

Esther Duruchukwu

Auto-generated profile, based on publicly available information

Esther Duruchukwu

Department of Radiation Oncology Northern Sydney Cancer Centre, Royal North Shore Hospital St Leonards New South Wales Australia

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
19 August 2025 in Journal of Medical Imaging and Radiation Oncology
Verified
Journal Article
Open access
EDEsther Duruchukwu
Esther Duruchukwu
ALAnna Lawless
Anna Lawless
DJDasantha Jayamanne
Dasantha Jayamanne
DVDavid Veivers
David Veivers
AWAndrew Wignall
Andrew Wignall
SBSarah Bergamin
Sarah Bergamin
Introduction: Long term survival for adenoid cystic carcinoma (ACC) arising from the head and neck declines for many decades after initial treatment due to late disease relapse. Follow up and surveillance imaging practices vary due to limited evidence as well as a lack of international guidelines (until 2021).Methods: A retrospective cohort study was conducted for patients treated curatively for ACC between 2007 and 2024 at a single institution. Clinicopathologic information, treatment details, patterns of follow‐up (including radiologic investigations) and oncological outcomes are reported.Results: 51 patients comprised the study cohort. Median age was 50 years; 96% of patients underwent surgery and adjuvant radiation therapy. Median follow‐up was 7.65 years. 5‐year overall survival (OS) and disease‐free survival (DFS) were 88% and 73% respectively. 18% and 61% of patients underwent surveillance imaging within 3‐ and 12‐months of treatment completion respectively. 80% of first recurrences were detected on surveillance imaging. Half the episodes of first disease recurrence occurred within 5 years of initial treatment, a further 25% within 10 years and the remaining 25% occurred > 10 years post treatment.Conclusion: This cohort of patients curatively treated for ACC at a single institution highlights the propensity for late distant relapse as well as heterogeneity of surveillance imaging. A local institutional protocol is proposed based upon the 2021 ASCO guidelines to standardise clinical and radiologic follow‐up for this group.

7 October 2026 in Cancer Reports
Verified
Journal Article
Open access
PDF file
ALAnna Lawless
Anna Lawless
DJDasantha Jayamanne
Dasantha Jayamanne
LPLisa Parker
Lisa Parker
EDEsther Duruchukwu
Esther Duruchukwu
PMPaula Macleod
Paula Macleod
SBSarah Bergamin
Sarah Bergamin
Background: Radiation therapy (RT) is central to curative treatment for oropharyngeal squamous cell carcinoma (OPSCC) but may cause late side effects that can adversely impact quality of life (QOL). As OPSCC treatment becomes more personalised, clinically meaningful QOL endpoints and their predictors are increasingly important. Aims: To assess long‐term QOL, treatment regret, and predictors of QOL after curative‐intent RT for OPSCC. Methods and Results: This cross‐sectional survey included patients with primary OPSCC treated with curative intent RT between 2007 and 2023 at a single tertiary institution. Patients completed validated EORTC QOL questionnaires and additional items assessing perceived health and treatment regret. Survival outcomes were estimated using Kaplan–Meier methods, and compared by p16 status using log‐rank test. QOL scores were analysed as continuous variables using univariate and multivariable linear regression models, with prespecified dosimetric predictors tested against clinically corresponding EORTC QOL‐HN43 symptom scales and adjusted for multiple comparisons. Of the 344 patients treated, 274 (80%) had p16‐positive disease. At median follow of 7.7 years, 5‐year overall survival was 90% for p16‐positive versus 52% for p16‐negative disease, and disease‐free survival 89% versus 72%. Of 232 patients contacted, 186 (80%) completed the QOL survey at median 6.3 years after RT. 173 (93%) reported no treatment regret regarding RT. Mean global health status was 81.3/100, while dry mouth/sticky saliva was the most affected domain (mean 41.9/100). On multivariable analysis, older age was associated with worse global health status (−4.9 points per 10 years, p = 0.001) and higher contralateral mean parotoid dose with worse dry mouth/sticky saliva scores (10.1 points per 10 Gy, 95% CI: 3.7 to 16.5, p = 0.002). Chemotherapy and prior surgery were not associated with any domain. Conclusion: Long‐term survivors of OPSCC reported favourable global QOL and little treatment regret after RT. However, dry mouth/sticky saliva remained a substantial burden, and more likely with higher contralateral parotid mean dose. These findings support ongoing contralateral parotid sparing and consideration of unilateral neck irradiation when oncologically appropriate, while recognising the cross‐sectional cohort and need for rigorous prospective studies in this area.